ClearView has introduced a revised framework for mandatory medical underwriting requirements across its product range. These changes, says the firm, aim to provide greater clarity and consistency for advisers and clients during the application process.
Highlights of the May 2025 updates include:
- Clients applying for cover under certain thresholds – up to $2m for life and TPD in some age groups – will benefit from reduced or no mandatory medical requirements, streamlining the application process
- The updated requirement tables for life, TPD, trauma, IP, and business expenses are now grouped into tiers, based on age and benefit amount
“This approach makes it easier for advisers to identify the necessary medical evidence and manage client expectations,” states the firm.
In addition, for higher levels of trauma cover, ClearView now incorporates alignment with the National Bowel Cancer Screening Program for applicants aged 50 and over, “…further reinforcing the link between underwriting and broader health outcomes”.
Trauma update
With effect from 5 July, the firm changed the trauma benefits available under its ClearChoice and LifeSolutions products. These enhancements, states the firm, aim to improve the clarity and fairness of trauma definitions while “…ensuring they remain aligned with contemporary medical practice”.
Key updates include:
- The exclusion for colorectal neuroendocrine carcinomas has been removed from the cancer definition under ClearChoice policies
- Coronary artery angioplasty, triple vessel – surgical procedure. The requirement for procedures to be performed on three specific named arteries has been broadened to include any three or more coronary arteries – improving applicability for a wider range of clinically equivalent procedures
- Major head trauma – significant permanent impairment. A new assessment pathway has been introduced, allowing claims to be assessed using a whole person impairment measure of at least 25% as an alternative to the ‘activities of daily living’ criteria
These changes apply to all existing ClearChoice and LifeSolutions policies, as well as to new policies issued before the firm’s next product disclosure statement update. They will apply to claims where the condition or symptoms first present on or after 5 June 2025. ClearView notes the updates do not result in any change to premium levels.
